

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 29,081,672

Date: 05/08/2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued development work on upgrades to its mobile apps and cloud-based platform to improve efficiency and accuracy and to add new feature sets. It also furthered its discussions with potential channel partners and other potential users of the technology.

Additionally, the Issuer named Mr Nick Watters as director in place of John Cook.

The Issuer announced that it received confirmation of its DTC eligibility, to assist in the ease of trading for US investors and brokers.

Finally, the Issuer continued contract work towards completion of a strategic partnership and equity interest in the Paris, France based company, Tech2Health, a company with a suite of products for the digital administration of mental health solutions.

2. Provide a general overview and discussion of the activities of management.

During the month, management has been primarily engaged in the improvement of Health Gauge's technology along with development of strategic partners arrangements and marketing plans for HG. Additionally, management was engaged in the conducting of due diligence regarding the acquisition of Tech2Health, along with contract preparation, and ongoing due diligence regarding other potential acquisitions.

3. Describe and provide details of any new products or services developed or offered.

None.

4. Describe and provide details of any products or services that were discontinued.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer retained Volt Strategic as a capital markets and communications advisor. Under the terms of the agreement with Volt Strategic, the Issuer will pay Volt Strategic \$5,000 per month over a term of six months. The agreement may be terminated at any time on written notice by the Company or Volt Strategic.

The Issuer has also granted incentive stock options to consultants of Volt Strategic to purchase up to 50,000 common shares in the capital of the Issuer, pursuant to the share option plan of the Issuer. The options are exercisable on or before July 5, 2023, at an exercise price of \$0.80 per share and will vest quarterly in equal amounts over the first twelve months. In addition, the Issuer has agreed to issue 125,000 common shares to consultants of Volt Strategic. The stock options and common shares issuable upon exercise of the options granted herein are subject to resale restrictions imposed by applicable law or regulation, including a statutory hold period expiring four months and one day from the date of grant.

Further, the Issuer retained Venture Liquidity Providers Inc. ("VLP") to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Company.

VLP is a specialized consulting firm providing a variety of services focused on publicly listed stocks. VLP's exclusive market-making service is provided by W.D. Latimer Co. Limited. ("Latimer"), a registered investment dealer, in compliance with all applicable laws and the policies of the Canadian Securities Exchange (the "CSE"). The finances and the shares required for the market-making service are provided by W.D. Latimer. The fee paid by the Company to VLP is for services only.

For its services, the Issuer has agreed to pay VLP \$5,000 per month for a period of three months, continuing on a month-to-month basis thereafter. The agreement may be terminated at any time on written notice by the Company or VLP.

The Issuer has also granted incentive stock options to consultants of VLP to purchase up to 50,000 common shares in the capital of the Issuer, pursuant to the share option plan of the Issuer. The options are exercisable on or before July 5, 2023, at an exercise price of \$0.80 per share and will vest quarterly in equal amounts over the first twelve months.

The Issuer is at arm's length with both Volt Strategic and VLP. To the knowledge of the Issuer's management, Volt Strategic and VLP do not have any present interest, directly or indirectly, in the Issuer or its securities, other than the compensation which the Issuer has granted pursuant to the agreements disclosed herein.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.
None.
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
None.
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
None.
- 14. Provide details of any securities issued and options or warrants granted.
The Issuer granted the following Options to consultants:

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Stock options grant	100,000	@0.80 until 5-Jul-23	
Stock options grant	100,000	@0.80 until 15-Jul-22	
Stock options grant	200,000	@0.80 until 15-Jul-23	

- 15. Provide details of any loans to or by Related Persons.
None.
- 16. Provide details of any changes in directors, officers or committee members.
Mr Nick Watters joined the board of directors with the retirement of John Cook, due to health reasons.

Mr. Watters is and has been a Director of several Public Companies and brings an extensive record of Corporate Governance experience to AIML. Mr. Watters is a co-founder of several successful early stage start up enterprises. He has been an integral part of raising nearly \$260 million for start-up and development opportunities in his career in a wide variety of sectors including mining, high-tech and the biotech industries. Mr. Watters is currently Business Development for East Africa Metals Inc. as well as serving as Director to several other Public Companies. He has been the President of his own private investment vehicle, Talisman Venture Partners since 1999.
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance has been expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the


most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 05/08/2021.

Tim Daniels
 Name of Director or Senior
 Officer

 Signature
 Executive Chairman
 Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		July 2021	YY/MM/D
AI/ML Innovations Inc.			21/08/05
Issuer Address			
Suite 203, 645 Fort St.			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Victoria, BC V8W 1G2			(778) 405-0882
Contact Name		Contact Position	Contact Telephone No.
Tim Daniels		Director	250 483-5650
Contact Email Address		Web Site Address	
tim.daniels@aiml-innovations.com		aiml-innovations.com	